National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2012 (No. 5) (No. PB 39 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L01458

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 39 of 2012
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2012 (No. 5)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, FELICITY MCNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated        29 June 2012
 
 
 
 
 
 
 
 
 
 
 
 
 
FELICITY MCNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________________
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2012 (No.5).
 
(2)                This Instrument may also be cited as PB 39 of 2012.
 
2             Commencement
This Instrument commences on 1 July 2012.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1                   Amendments
[1]      Section 4, after definition for other Special Arrangement
insert:
paperless claim for payment has the meaning given in the Regulations.
 
[2]      Section 4, after definition for streamlined authority code
insert:
supply certification form has the meaning given in the Regulations.
 
[3]      After subsection 33(2)
insert:
(3)       Subregulation 31(4) of the Regulations does not apply to a paperless claim for payment submitted in accordance with this Subdivision.
Note Subregulation 31(4) provides that an approved supplier commits an offence if a paperless claim for payment is made and a completed supply certification form is not included.
 
[4]    Schedule 1, entry for Abatacept
omit from the column headed ‘Section 100 Only’:
D
substitute:
PB
 
[5]    Schedule 1, entry for Clozapine in the form Tablet 25 mg with manner of administration Oral and brand Clozaril 25
insert in the column headed ‘Section 100 Only’:
D
[6]    Schedule 1, entry for Clozapine in the form Tablet 100 mg with manner of administration Oral and brand Clozaril 100
insert in the column headed ‘Section 100 Only’:
D
 
[7]    Schedule 1, entry for Cyclosporin in the form Capsule 25 mg with manner of administration Oral and brand Neoral 25
insert in the column headed ‘Section 100 Only’:
C
 
[8]    Schedule 1, entry for Cyclosporin in the form Capsule 50 mg with manner of administration Oral and brand Neoral 50
insert in the column headed ‘Section 100 Only’:
C
 
[9]    Schedule 1, entry for Cyclosporin in the form Capsule 100 mg with manner of administration Oral and brand Neoral 100
insert in the column headed ‘Section 100 Only’:
C
 
[10]  Schedule 1, entry for Levodopa with Carbidopa
omit from the column headed ‘Section 100 Only’:
D
substitute:
C
 
[11]  Schedule 1, entry for Pamidronic Acid in the form Concentrated injection containing disodium pamidronate 90 mg in 10 mL
omit from the column headed ‘Section 100 Only’:
C
substitute:
PB
 
[12]  Schedule 1, entry for Pamidronic Acid in the form Injection set containing 1 vial powder for I.V infusion containing disodium pamidronate 90 mg and 1 ampoule solvent 10 mL
omit from the column headed ‘Section 100 Only’:
C
substitute:
PB
 
 
[13]  Schedule 1, entry for Zoledronic Acid
Omit from the column headed ’Circumstances’:
C3881 C3882
Insert after C3343:
C4051 C4052
 
[14]  Schedule 3, entry for Zoledronic Acid
omit:
 
C3881
 
Where the patient is receiving treatment at/from a private hospital
Bone metastases from hormone-resistant prostate cancer;
Compliance with Written or Telephone Authority Required procedures
substitute:
 
C4051
 
Where the patient is receiving treatment at/from a private hospital
Bone metastases from castration-resistant prostate cancer
Compliance with Written or Telephone Authority Required procedures
 
[15]  Schedule 3, entry for Zoledronic Acid
omit:
 
C3882
 
Where the patient is receiving treatment at/from a public hospital
Bone metastases from hormone-resistant prostate cancer
Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 3882
substitute:
 
C4052
 
Where the patient is receiving treatment at/from a public hospital
Bone metastases from castration-resistant prostate cancer
Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 4052
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.